Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 11, Special Issue 10 (2022)

Assessing the antidiabetic activity of peptides obtained from chicken intestine hydrolysate in canine pellet food using alpha amylase inhibitory assay

Author(s):
E Vimalraj, R Ramani, V Appa Rao, M Parthiban, R Narendra Babu, A Abinaya and S Arulkumar
Abstract:
Chicken intestine was hydrolysed by protease P food grade fungal enzyme. Chicken intestinal hydrolysate was ultrafiltered using 10kda molecular weight cut-off and the filtrate is freeze dried. Then the low molecular weight peptides is incorporated in canine pellet feed at 5%, 6% and 7% levels. Canine pellet feed with different levels of incorporated peptides was assessed for antidiabetic activity using α-amylase inhibitory assay. The mean±SE values of IC50 value for anti-diabetic activity of bioactive peptide incorporated at different levels of 5%, 6% and 7% in canine pet food were 59.26±4.4 mg/ml, 364.28±13 mg/ml and 163.57±5.04 mg/ml respectively.
These values were then compared with the IC50 value for anti-diabetic activity of canine pet food prior to addition of bioactive peptides. Which was taken as control is 1313.85±52.8. The test of significance revealed that there was a highly significant difference between the different levels of bioactive peptides incorporated canine pet food. The 5% inclusion level was found to have less IC50 value of 59.26±4.4 µg/ml and better alpha amylase inhibition activity. The canine pet food with 5% incorporated bioactive peptides had lower IC50 value than the other levels indicating that the potency of the extracted peptides has been exhibited in the incorporated canine pet food.
Pages: 861-863  |  202 Views  104 Downloads
How to cite this article:
E Vimalraj, R Ramani, V Appa Rao, M Parthiban, R Narendra Babu, A Abinaya and S Arulkumar. Assessing the antidiabetic activity of peptides obtained from chicken intestine hydrolysate in canine pellet food using alpha amylase inhibitory assay. The Pharma Innovation Journal. 2022; 11(10S): 861-863.

Call for book chapter